Achillion-Logo-150 (4).jpg
Achillion to Present at the 2017 JMP Securities Life Sciences Conference
June 15, 2017 16:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., June 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion-Logo-150 (4).jpg
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
May 04, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2017. For the first quarter of...
Achillion-Logo-150 (4).jpg
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 02, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Akari Logo (1).jpg
Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
April 24, 2017 07:15 ET | Akari Therapeutics, Plc
-Interim Phase 2 PNH data demonstrate positive response with Coversin™-Phase 3 PNH program expected to commence in 4Q2017-Data from preclinical aHUS model demonstrates positive results-New preclinical...
Achillion-Logo-150 (4).jpg
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
April 06, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., April 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced initiation of patient dosing in a Phase 2 open-label study of ACH-4471,...
Akari Logo (1).jpg
Akari Therapeutics to Present at the Jefferies Complement Symposium
April 03, 2017 07:00 ET | Akari Therapeutics, Plc
NEW YORK and LONDON, April 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Logo (1).jpg
Akari Therapeutics Announces FDA Fast Track Designation For Coversin
March 30, 2017 16:02 ET | Akari Therapeutics, Plc
NEW YORK and LONDON, March 30, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug...
Akari Logo (1).jpg
Akari Therapeutics Announces R&D Day on April 24, 2017
March 17, 2017 07:00 ET | Akari Therapeutics, Plc
NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research...
Akari Logo (1).jpg
Akari Therapeutics to Present at the 29th Annual ROTH Conference
March 07, 2017 07:00 ET | Akari Therapeutics, Plc
NEW YORK and LONDON, March 07, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Achillion-Logo-150 (4).jpg
Achillion Reports 2016 Fourth Quarter and Year-End Financial Results
February 23, 2017 16:05 ET | Achillion Pharmaceuticals, Inc.
Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017Expanding complement platform includes internally...